We are a Vancouver, BC based biotech firm and an emerging leader in the discovery and development of new drugs for the treatment of infectious diseases.

Upstream Biosciences designs new drugs, and repurposes existing drugs, using novel computational chemistry pattern matching techniques to treat antibiotic-resistant infectious diseases and cancer. Our innovative approach to drug discovery uses a proprietary artificial intelligence software platform to rapidly and cost effectively generate and optimize drug candidates by leveraging historic test data. Upstream’s process produces a continuous stream of drug candidates and has demonstrated a one in four success rate compared to the pharmaceutical industry average of one in 10,000.

Our technology has already generated novel drug candidates that, in preclinical laboratory studies and animal studies, demonstrate both human and veterinary potential against major tropical parasitic diseases. Testing of lead compounds have demonstrated in vitro efficacy and in vivo safety against such diseases as Malaria, African Sleeping Sickness, Nagana and Leishmaniasis.

While our initial focus has been on neglected tropical diseases, we believe our proprietary methodology could be applied to a diverse range of illnesses with potential for success. These include various chemotherapy drugs and anti-biowarfare agents (cryptosporidium), drug-resistant tuberculosis and HIV.

We have filed over seven provisional patents with regards to our technologies. It is our plan to continue to protect our Intellectual Property through a combination of trade secret and provisional patents, prior to filing Initial Patent Applications with the USPTO and throughout the Patent Cooperation Treaty (PCT) territories. We plan to file our Initial Patent Applications on drug composition and process once our lead drug candidates have been internally selected to go into Clinical Trials.

© 2006 Upstream Biosciences Inc. ~ all rights reserved

LEGAL NOTICE
The information provided through this website is intended solely for the general knowledge of visitors to the website and does not constitute an offer or a solicitation of an offer for the purchase or sale of any shares or other securities of Upstream Biosciences Inc.

NOTICE REGARDING FORWARD-LOOKING STATEMENTS
The information contained within this website contains “forward-looking statements”, as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Statements in this website, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future.
Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others: (i) the risk that that management is unable to execute the business plan; (ii) the risk that the company fails to obtain financing; (iii) the risk that the company’s patent applications are rejected by the USPTO or that, for whatever reason there is a failure to protect IP; (iv) the risk that key members of the management team leave or are terminated; and (iv) any other factor. These forward-looking statements are updated periodically. Although Upstream Biosciences Inc. believes that the beliefs, plans, expectations and intentions contained in this website are reasonable, there can be no assurance those beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consider all of the information set forth in this notice and should also refer to the risk factors disclosed in Upstream Bioscience Inc.’s periodic reports filed from time-to-time with the Securities and Exchange Commission and available at www.sec.gov.